Related Experiment Videos
[Clinical effect of allylestrenol on benign prostatic hypertrophy]
Hinyokika Kiyo. Acta Urologica Japonica
|March 1, 1986
Summary
Allylestrenol shows promise for treating benign prostatic hypertrophy (BPH). In a study of 45 patients, 55% experienced improvements with this medication, with generally mild side effects.
Area of Science:
- Urology
- Pharmacology
Context:
- Benign prostatic hypertrophy (BPH) is a common condition in aging men.
- Current BPH treatments have varying efficacy and side effect profiles.
Purpose:
- To evaluate the efficacy and safety of allylestrenol in patients with BPH.
- To determine the potential of allylestrenol as a therapeutic option for BPH.
Summary:
- A total of 45 patients with BPH were treated with 50 mg of allylestrenol daily.
- Over 12 weeks, 22 patients (55%) showed marked or moderate improvements.
- Reported side effects included decreased potency, libido, breast pigmentation, palpitations, shortness of breath, and gastrointestinal issues, all deemed non-serious.
Impact:
- Allylestrenol may offer a viable treatment option for benign prostatic hypertrophy.
- Further research could establish allylestrenol's role in urological clinics for BPH management.